Clinical Trials Browser

Completed × Pathologic Complete Response × pembrolizumab × Clear all

NCT04435197 2024-07-03

PALACE-2

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response